Published in Subst Abus on January 01, 2014
The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil (2017) 0.76
Marijuana for Glaucoma: A Recipe for Disaster or Treatment? Yale J Biol Med (2015) 0.75
A review of the published literature into cannabis withdrawal symptoms in human users. Addiction (2002) 3.65
Natural recovery from alcohol and drug problems: methodological review of the research with suggestions for future directions. Addiction (2000) 2.47
Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) (1999) 2.27
Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat (2008) 1.73
Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry (2008) 1.59
The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend (2011) 1.52
Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol (1982) 1.41
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend (2010) 1.27
A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev (2003) 1.26
The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: multisite study of differences between general population and treatment groups. Addict Behav (2008) 1.24
An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction (1996) 1.23
Consistency between adolescent reports and adult retrospective reports of adolescent marijuana use: explanations of inconsistent reporting among an African American population. Drug Alcohol Depend (2006) 1.19
Marijuana use and treatment outcome among opioid-dependent patients. Addiction (1998) 1.16
Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend (2008) 1.15
Advances in the field of cannabinoid--opioid cross-talk. Addict Biol (2008) 1.14
Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend (2003) 1.14
Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl) (2010) 1.11
Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction (2008) 1.05
Spontaneous remission from alcohol, tobacco, and other drug abuse: seeking quantitative answers to qualitative questions. Am J Drug Alcohol Abuse (2000) 1.05
A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med (2012) 1.00
Inconsistencies in lifetime cocaine and marijuana use reports: impact on prevalence and incidence. Addiction (1995) 1.00
Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. J Neurochem (2008) 0.96
Repeated exposure to methamphetamine, cocaine or morphine induces augmentation of dopamine release in rat mesocorticolimbic slice co-cultures. PLoS One (2011) 0.91
Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res (2012) 0.84
Cannabinoid-opioid interactions in drug discrimination and self-administration: effect of maternal, postnatal, adolescent and adult exposure to the drugs. Curr Drug Targets (2010) 0.84
Positron emission tomography molecular imaging of dopaminergic system in drug addiction. Anat Rec (Hoboken) (2012) 0.80
Self-reported sleep disturbances during cannabis withdrawal in cannabis-dependent outpatients with and without opioid dependence. Sleep Med (2010) 0.80
[Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence]. Encephale (2011) 0.78
Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med (2004) 4.55
Why should addiction medicine be an attractive field for young physicians? Addiction (2008) 3.52
Introduction to behavioral addictions. Am J Drug Alcohol Abuse (2010) 3.22
HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res (2007) 2.55
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
Use of a 'microecological technique' to study crime incidents around methadone maintenance treatment centers. Addiction (2012) 2.20
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet (2006) 1.93
The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav (2002) 1.74
Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry (2012) 1.67
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Cocaine craving and use during daily life. Psychopharmacology (Berl) (2009) 1.62
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend (2009) 1.42
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Questions on conflict of interest. Am J Psychiatry (2010) 1.38
NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci (2003) 1.36
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) (2007) 1.32
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine Tob Res (2003) 1.28
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend (2005) 1.20
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug Alcohol Depend (2007) 1.08
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
State of the art treatments for cannabis dependence. Psychiatr Clin North Am (2012) 1.07
Calorie restriction increases cigarette use in adult smokers. Psychopharmacology (Berl) (2004) 1.06
The second-oldest state psychiatric hospital in the United States. Am J Psychiatry (2014) 1.06
Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res (2007) 1.05
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry (2010) 1.05
Pharmacological treatment of cannabis dependence. Curr Pharm Des (2011) 1.04
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal (2014) 1.03
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01
Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol (2006) 1.01
Strategies for quitting among non-treatment-seeking marijuana smokers. Am J Addict (2005) 1.00
Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction (2010) 0.98
Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse (2010) 0.98
Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin Chim Acta (2012) 0.97
Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend (2011) 0.97
Double jeopardy--drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial. Subst Abuse Treat Prev Policy (2012) 0.97
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol (2008) 0.96
Longitudinal ECG changes in cocaine users during extended abstinence. Drug Alcohol Depend (2008) 0.95
Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin Chem (2012) 0.95
Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. Int J Drug Policy (2008) 0.94
Nondisclosure of HIV infection to sex partners and alcohol's role: a Russian experience. AIDS Behav (2013) 0.94
Twice stigmatized: provider's perspectives on drug-using women in the Republic of Georgia. J Psychoactive Drugs (2013) 0.94
Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol (2012) 0.93
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Anal Bioanal Chem (2013) 0.91
Mutation screen of the GAD2 gene and association study of alcoholism in three populations. Am J Med Genet B Neuropsychiatr Genet (2007) 0.90
Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. Anal Bioanal Chem (2011) 0.90
Psychosocial and contextual correlates of opioid overdose risk among drug users in St. Petersburg, Russia. Harm Reduct J (2009) 0.90
Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. Eur J Pharmacol (2005) 0.90
Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? Clin Chem (2013) 0.89
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
EEG absolute power during extended cocaine abstinence. J Addict Med (2007) 0.89
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev (2015) 0.87
HERMITAGE--a randomized controlled trial to reduce sexually transmitted infections and HIV risk behaviors among HIV-infected Russian drinkers. Addiction (2014) 0.87
Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration. Clin Chem (2011) 0.86
Motivations to quit cannabis use in an adult non-treatment sample: are they related to relapse? Addict Behav (2013) 0.86
Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs. AIDS Care (2014) 0.85
Spending of remuneration by subjects in non-treatment drug abuse research studies. Am J Drug Alcohol Abuse (2006) 0.85
Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers? Drug Alcohol Depend (2013) 0.85
Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict (2014) 0.84
Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat (2005) 0.84
Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res (2012) 0.84
In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Anal Bioanal Chem (2013) 0.84
Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. J Anal Toxicol (2009) 0.84
MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration. Ther Drug Monit (2011) 0.84
Associations between partner violence perpetration and history of STI among HIV-infected substance using men in Russia. AIDS Care (2012) 0.84
Gender differences in neurocognitive functioning among alcohol-dependent Russian patients. Alcohol Clin Exp Res (2007) 0.83
Sociodemographic characteristics associated with substance use status in a trauma inpatient population. J Addict Dis (2007) 0.83
Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. AIDS Care (2014) 0.83
Injectable extended-release naltrexone for opioid dependence. Lancet (2011) 0.83
Pain is associated with heroin use over time in HIV-infected Russian drinkers. Addiction (2013) 0.83
Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. Clin Chem (2009) 0.82
Women who inject drugs in the republic of georgia: in their own words. J Psychoactive Drugs (2015) 0.82
Lost-to-care and engaged-in-care HIV patients in Leningrad Oblast, Russian Federation: barriers and facilitators to medical visit retention. AIDS Care (2014) 0.82
Risk of psychoactive substance dependence among substance users in a trauma inpatient population. J Addict Dis (2007) 0.82
Incorporation of methamphetamine and amphetamine in human hair following controlled oral methamphetamine administration. Anal Chim Acta (2012) 0.82
Serotonergic responsiveness in human cocaine users. Drug Alcohol Depend (2006) 0.81
Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. Drug Test Anal (2014) 0.81
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond? J Addict Med (2015) 0.81
Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. Anal Bioanal Chem (2013) 0.80
Self-reported sleep disturbances during cannabis withdrawal in cannabis-dependent outpatients with and without opioid dependence. Sleep Med (2010) 0.80
Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict (2009) 0.80
The French law on "protection of persons undergoing biomedical research": implications for the U.S. J Law Med Ethics (2003) 0.79
Addiction treatment in Russia. Lancet (2010) 0.79
Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend (2012) 0.79
Reduced cannabis use after low-dose naltrexone addition to opioid detoxification. J Clin Psychopharmacol (2010) 0.78
Depressive symptoms and antiretroviral therapy (ART) initiation among HIV-infected Russian drinkers. AIDS Behav (2014) 0.78
Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. Clin Chem (2011) 0.78
CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse (2011) 0.78
Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine Tob Res (2013) 0.78
Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. Anal Bioanal Chem (2014) 0.77